Rafael Pharmaceuticals announces expansion of Phase 2 trial of CPI-613
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613 for patients with relapsed or refractory Burkitt's lymphoma/leukemia. The clinical trial will begin enrolling patients at Massachusetts General Hospital in Boston starting this month. The trial is currently underway at Memorial Sloan Kettering Cancer Center in New York City and at City of Hope in Duarte, California. In June 2018, devimistat received orphan drug designation for the treatment of relapsed Burkitt's lymphoma from the U.S. Food and Drug Administration. Orphan drug designation refers to a special status granted by The Orphan Drug Act to a drug used to treat a rare disease or condition.